CAPRICOR THERAPEUTICS, INC.

Capricor Therapeutics is a biotechnology company that develops cell and exosome therapeutics for rare diseases and conditions with significant unmet medical need, primarily Duchenne muscular dystrophy. Its lead product candidate is Deramiocel, an investigational cardiac-derived cell therapy aimed at reducing cardiac and skeletal muscle decline in individuals with muscular dystrophy. The company also develops an engineered exosome platform called StealthX for vaccines and targeted therapies, including a candidate for COVID-19. Since Capricor currently has no approved commercial products, it collaborates with commercial partners and research institutions such as Nippon Shinyaku rather than selling directly to commercial consumers, targeting patients with severe degenerative disorders.

The company operates its corporate headquarters and primary manufacturing site in San Diego, California, which includes cleanroom suites and quality control laboratories. Capricor also maintains a secondary leased manufacturing space in Los Angeles, California. Its clinical research and regulatory activities are conducted across clinical sites in the United States, with distribution partnerships and regulatory engagements extending to Japan and Europe.

Summary of the business section of Capricor Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 231 employees, all of whom were full-time employees, and 59 of whom held advanced degrees.”